{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:09:20Z","timestamp":1789142960477,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.medj.2026.101271","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:32:45Z","timestamp":1789140765000},"page":"101271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond treatment intensification: The next questions after CAPITAL"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9218-2009","authenticated-orcid":false,"given":"Rei","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101271_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101258","article-title":"Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II\u2013III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial","volume":"7","author":"Nie","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.medj.2026.101271_bib2","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101271_bib3","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101271_bib4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10120-023-01419-9","article-title":"Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in stage III gastric cancer: a final report of the JACCRO GC-07 study","volume":"26","author":"Kodera","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.medj.2026.101271_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10120-024-01556-9","article-title":"Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer","volume":"28","author":"Iden","year":"2025","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.medj.2026.101271_bib6","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.23.02167","article-title":"Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY","volume":"42","author":"Kang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101271_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(24)00676-4","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101271_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101271_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/jjco\/hyac154","volume":"53","author":"Mizusawa","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101271_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:32:58Z","timestamp":1789140778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026002746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666634026002746"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101271","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond treatment intensification: The next questions after CAPITAL","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101258","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101271"}}